Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ADMA Biologics

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.

Investors Business Daily

ADMA Biologics Sees Composite Rating Move Up To 96

ADMA Biologics Sees Composite Rating Move Up To 96

The IBD SmartSelect Composite Rating for ADMA Biologics rose from 93 to 96 Friday.

Investors Business Daily

ADMA Biologics Sees Composite Rating Climb To 96

ADMA Biologics Sees Composite Rating Climb To 96

ADMA Biologics saw its IBD SmartSelect Composite Rating rise to 96 Tuesday, up from 94 the day before.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

ADMA Biologics, A Top 1% Stock, Skyrockets After Settling Its Accounting Debacle

ADMA stock rocketed Friday after the biotech company inked a deal with KPMG as its new independent registered public accounting firm.

Investors Business Daily

IBD 50's Top Stock, ADMA Biologics, Crashes After Auditor Unexpectedly Resigns

ADMA stock plummeted Thursday after the company's auditor unexpectedly resigned. But ADMA Biologics kept its guidance for this year and next.

Investors Business Daily

The Real Best Stock Of The Year Isn't In The S&P 500 Yet

If you're like most investors — you assume AI giant Nvidia is the best stock of the year. But 2024's major champ isn't even in the S&P 500.

Investors Business Daily

Chart of the Day: ADMA Biologics - Hitting New Highs

The Chart of the Day belongs to the biomedical company ADMA Biologics (ADMA) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart...

inkl

Read news from The Economist, FT, and more,
with one subscription

Why ADMA Biologics Shares Are Rising Today

Why ADMA Biologics Shares Are Rising Today

ADMA Biologics Inc (NASDAQ: ADMA) shares are trading higher Monday after the company announced it received U.S. Food and Drug Administration approval for its sixth plasma collection center.

Looking Into ADMA Biologics's Return On Capital Employed

Looking Into ADMA Biologics's Return On Capital Employed

Benzinga Pro data, ADMA Biologics (NASDAQ:ADMA) reported Q1 sales of $29.10 million. Earnings fell to a loss of $25.01 million, resulting in a 50.2% decrease from last quarter.

Recap: ADMA Biologics Q1 Earnings

Recap: ADMA Biologics Q1 Earnings

ADMA Biologics (NASDAQ:ADMA) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings ADMA Biologics missed estimated earnings by 25.0%, reporting an EPS of $-0.1 versus an estimate of $-0.08.

Earnings Outlook For ADMA Biologics

Earnings Outlook For ADMA Biologics

ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that ADMA Biologics will report an earnings per share (EPS) of $-0.08.

ADMA Biologics's Return On Capital Employed Overview

ADMA Biologics's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q4, ADMA Biologics's (NASDAQ:ADMA) reported sales totaled $26.38 million. Despite a 6.0% increase in earnings, the company posted a loss of $16.65 million.

ADMA Biologics' Q4 Top-Line Surpass Estimates, Concludes $175M Debt Refinancing

ADMA Biologics' Q4 Top-Line Surpass Estimates, Concludes $175M Debt Refinancing

ADMA Biologics Inc (NASDAQ: ADMA) closed a debt refinancing with Hayfin Capital Management of $150 million, and up to an additional $25 million tied to specific revenue targets during 2022.

ADMA Biologics's Earnings Outlook

ADMA Biologics's Earnings Outlook

ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Thursday, 2022-03-24. Here's what investors need to know before the announcement. Analysts estimate that ADMA Biologics will report an earnings per share (EPS) of $-0.09.

Get all your
news in one place.

100’s of premium titles.
One news app.

People

Robert F. Kennedy Jr

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

SP Global Market Intelligence

Lumen Technologies

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play